Detection
Encompass Diagnostics can detect more than 30 different types of wound pathogens and deliver 99% accurate results within 24-48 hours of lab sample receipt.
Encompass Diagnostics
We believe in fast results, unbeatable accuracy, and continually building on ever-changing technologies, whether we’re battling COVID-19 or breaking down wound samples. Encompass Diagnostics is certified according to the Clinical Laboratory Improvement Amendment (CLIA) for high complexity molecular testing and moderate complexity clinical testing. Using molecular testing, we’re able to provide a thorough breakdown of the pathogens causing an infection within 24-48 hours, making our lab reports and recommendations timely for gastrointestinal issues, women’s health, men’s health, wounds, and others. Our test panels include Wound, Nail, RPP, UTI, GI, Antibiotic resistance, COVID, and COVID with reflex to 4 variants.

Encompass Diagnostics was formed with one specific purpose: to impact and improve lives by empowering patients and their physicians with the information needed to improve their health. Our scientists and researchers work tirelessly to advance one of the most important developments in the history of medicine, Molecular Diagnostic Testing, allowing healthcare professionals to quickly diagnose and treat conditions with improved safety and accuracy. Our services include molecular pathogen testing, pharmacogenetics, and other specialty molecular testing. Encompass Diagnostics also provides high capacity COVID-19 testing for individuals and workplace environments nationwide.
Encompass Diagnostics can detect more than 30 different types of wound pathogens and deliver 99% accurate results within 24-48 hours of lab sample receipt.
Encompass Diagnostics molecular pathogen testing is more accurate than standard culture testing. Our molecular pathogen testing detects anaerobic organisms growing deep inside a wound that standard cultures often miss.
Using a molecular approach, amplification of testing sample genetic material is faster than standard culture growth and delivers increased sensitivity and a quicker result.
Our rapid TAT is within 24-48 hours from laboratory receipt.
Our simple to read report gives clinicians quick, actionable intelligence to make better treatment decisions
Ability to identify pathogens when the patient is on empiric antibiotic therapy
With molecular testing, not only can you receive a clear picture of the type and percent of pathogens causing the infection. In many cases, you can identify antimicrobial resistance. With the power of molecular testing, you can select the optimal drug therapy for your patient, improve treatment outcomes and reduce healthcare spend.
For a full list of pathogens tested, please visit encompassdiagnostics.com
Molecular tests can be covered by Medicare and Medicaid. Commercial coverage will vary based upon geography and plan type, and typically requires prior authorization.
These comprehensive diagnostic tests are covered by most insurance carriers
Detection, Diagnosis and Treatment Designed for Senior Living Residents
According to the National Institutes of Health, about 6.7 million people in the U.S. are affected by chronic wounds. Residents with infected wounds can experience an abnormal healing process that may lead to longer-term care, additional medications, pain, stress, depression, hospitalization, function and mobility loss. The result is higher costs for healthcare organizations and residents alike.
Encompass Diagnostics combines advancements in molecular diagnostics and drug efficacy data, then puts that information into actionable resident-centered reports.

With Encompass Diagnostics, you will receive therapeutic options for your residents based on effective medications for the positively identified pathogens cross-referenced with the antibiotic resistant markers. The result is a reduction in unnecessary medication exposure and adverse events.
Reduce unnecessary testing, improve resident satisfaction with the Encompass Diagnostics molecular PCR GI panel.

Molecular PCR testing is more accurate than standard culture and sensitivity testing, identifying – with 99% accuracy-all bacteria, viruses, parasites, and H Pylori with antimicrobial resistance. These tests can identify pathogens with 99% accuracy, even when the resident is on empiric antibiotic therapy.
Encompass Diagnostics combines advancements in molecular diagnostics and drug efficacy data into actionable patient-centered information to help physicians determine the most appropriate treatment regimen for each resident.
In nursing homes, as many as two thirds of residents receive antibiotics each year and up to 75% of these are estimated to be inappropriate.
The prevalence of UTI infections means that advanced diagnostics are critical for rapidly and accurately identifying the pathogens causing the infection. Improper diagnosis or treatment can lead to ongoing pain and discomfort, chronic infections, permanent kidney damage and life-threatening sepsis.2 Provide your residents with the Encompass Diagnostics Molecular PCR UTI test to treat UTIs effectively and safely, eliminating false negative and false positive results.

With the power of molecular testing, you can select the optimal therapy for your residents, improve treatment outcomes and reduce healthcare spend.
Encompass Diagnostics is certified according to the Clinical Laboratory Improvement Amendment of 1988 (CLIA) for high complexity molecular testing and moderate complexity clinical testing.
